There has been an important update in pediatric diabetes care.

Mounjaro® (tirzepatide) is now FDA-approved for use in pediatric patients aged 10 years and older with Type 2 diabetes, as an adjunct to diet and exercise to improve glycemic control.

Obesity and type 2 diabetes share intricate biological mechanisms that intertwine their effects on the body.

The main cause of type 2 diabetes is insulin resistance. Insulin is a hormone produced by the pancreas that helps glucose enter the body's cells to be used as energy.